首页>投融资
PsyBio Therapeutics
增发
PsyBio Therapeutics develops biosynthetic psychoactive compounds for the treatment of mental health issues such as depression, anxiety, PTSD, and substance dependency.In February 2021, Evan Levine, has acquired control and direction over 12,704.958 multiple voting shares of the Company and 2,970,000 options to purchase subordinate voting shares of the Company in connection with the Company recently completed reverse takeover of PsyBio Therapeutics,
基本信息
-
公司全称PsyBio Therapeutics Corp
-
类型新型心理靶向疗法研究商
-
产业领域研发制造服务、药品研发/制造、生物药
-
公司人数15人以下
-
地址9 Plaza Real South BOCA RATON FLORIDA 33432; US; Telephone: +15134499585;
-
联系电话513-449-9585
-
邮箱evan@psybiolife.com
-
成立时间2009-01-01
投融资
-
2023-01-16增发20.65万美元未透露
-
2023-01-05增发47.26万美元未透露
-
2021-07-14上市未透露未透露
相关投融资企业
未透露
Abiologics是一家生物技术公司的开发者打算通过开发一种叫做合成肽的新型生物制剂来彻底改变医学领域。该公司的平台利用尖端的生成式人工智能和高通量化学蛋白质合成来计算设计和化学合成超自然生物制剂，使制药和生物技术公司的客户能够有效地为患者带来挽救生命的治疗。该公司正在开创一类新的超自然和可编程生物制剂，称为Synteins™。Abiologics平台利用尖端的生成式人工智能和高通量化学蛋白质合成来创造具有强大、理想药理学特性的Synteins™，重新定义了治疗药物可以为一系列疾病领域的患者实现的目标。
B轮
Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health.In October 2020, Solarea Bio has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate investor
增发
PsyBio Therapeutics develops biosynthetic psychoactive compounds for the treatment of mental health issues such as depression, anxiety, PTSD, and substance dependency.In February 2021, Evan Levine, has acquired control and direction over 12,704.958 multiple voting shares of the Company and 2,970,000 options to purchase subordinate voting shares of the Company in connection with the Company recently completed reverse takeover of PsyBio Therapeutics,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息